Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies / Cazzaniga, M. E.; Verusio, C.; Ciccarese, M.; Fumagalli, A.; Sartori, D.; Valerio, M. R.; Airoldi, M.; Moretti, G.; Ficorella, C.; Gianni, L.; Michelotti, A.; Zambelli, A.; Febbraro, A.; Generali, D.; Pistelli, M.; Garrone, O.; Musolino, A.; Vici, P.; Maur, M.; Mentuccia, L.; La Verde, N.; Bianchi, G. V.; Artale, S.; Blasi, L.; De Laurentiis, M.; Atzori, F.; Turletti, A.; Porpiglia, M.; Santini, D.; Fabi, A.; Gebbia, V.; Schirone, A.; Palumbo, R.; Ferzi, A.; Frassoldati, A.; Scavelli, C.; Clivio, L.; Giordano, M.; Donadio, M.; Biganzoli, L.; Del Mastro, L.; Bisagni, G.; Livi, L.; Natoli, C.; Montemurro, F.; Riccardi, F.; Romagnoli, E.; Marchetti, P.; Torri, V.; Pronzato, P.; Mustacchi, G.. - In: BREAST CARE. - ISSN 1661-3791. - 15:1(2020), pp. 30-37. [10.1159/000495469]
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Michelotti A.;Musolino A.Writing – Review & Editing
;Porpiglia M.;Fabi A.;Giordano M.;Donadio M.;Del Mastro L.;Livi L.;Marchetti P.;
2020-01-01
Abstract
Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
